• 1
    Talpaz M, Kantarjian H, McCredie KB, Keating MJ, Gutterman JU. Chronic myelogenous leukemia: hematologic remissions and cytogenetic improvements induced by recombinant alpha A interferon. N Engl J Med. 1986; 314: 10651069.
  • 2
    Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987; 69: 12801288.
  • 3
    Kantarjian H, Deisseroth A, Kurzrock LR, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993; 82: 691703.
  • 4
    Kantarjian H, Smith T, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med. 1996; 122: 254261.
  • 5
    Allan NC, Richards SM, Shepherd PCA, et al. UK Medical Research Council randomized, multi-centre trial of interferon-α for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet. 1995; 345: 13921397.
  • 6
    The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998; 92: 15411548.
  • 7
    The Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol. 1999; 17: 18581868.
  • 8
    Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994; 330: 820825.
  • 9
    Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997; 89: 16161620.
  • 10
    Guilhot F, Chastang C, Michallet M, et al. Interferon-alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Myeloid Leukemia Study Group. N Engl J Med. 1997; 337: 223229.
  • 11
    Kantarjian H, O'Brien S, Smith T, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999; 17: 284292.
  • 12
    Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia. For the Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood. 2002; 99: 15271535.
  • 13
    Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996; 87: 30693081.
  • 14
    Faderl S, Talpaz M, Estrov Z, Kantarjian H. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999; 131: 207219.
  • 15
    Daley GQ, Van Etten RA, Baltimore D, et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990; 247: 824830.
  • 16
    Kelliher MA, McLaughlin J, Witte O, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA. 1990; 87: 66496653.
  • 17
    Mahon F, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon-α. J Clin Oncol. 2002; 20: 214220.
  • 18
    Bonifazi F, de Vivo A, Gianantonio R, et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood. 2001; 98: 30743081.
  • 19
    Giles F, Kantarjian H, O'Brien S, et al. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leuk Lymphoma. 2001; 41: 309319.
  • 20
    Druker B, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 10311037.
  • 21
    O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999; 93: 41494153.
  • 22
    Lee M, Khouri I, Champlin R, et al. Detection of minimal residual disease by polymerase chain reaction of BCR/ABL transcripts in chronic myelogenous leukemia following allogeneic bone marrow transplantation. Br J Haematol. 1992; 82: 708714.
  • 23
    Sokal J, Cox E, Baccarani M, et al., and the Italian Cooperative CML Study Group. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984; 63: 789799.
  • 24
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645652.
  • 25
    Talpaz M, Silver R, Druker B, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99: 19281937.
  • 26
    Sawyers C, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99: 35303539.
  • 27
    Kantarjian H, Cortes J, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003; 101: 97100.
  • 28
    Druker B, for the IRIS (International Randomized INF vs. STI571) Study Group. STI571 (Gleevec/Glivec, imatnib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study. Proc Am Soc Clin Oncol. 2002; 21: 1.
  • 29
    Kantarjian H, Talpaz M, Cortes J, et al. Quantitiative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic phase chronic myelogenous leukemia. Clin Cancer Res. 2003, in press.
  • 30
    Kantarjian H, Cortes J, O'Brien S, et al. High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph + CML-CP). Proc Am Soc Clin Oncol. 2002; 21: 261a.